KORTUC

Focus: KORTUC is a Japanese biotech startup founded in 2022 specializing in radiosensitizer development for oncology indications. The company is pre-revenue and currently in Series B funding stage with a focused pipeline in early clinical development.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES B

Open Jobs

About KORTUC

AI assessmentNot Hiring

No open roles listed right now. Follow KORTUC to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

KRC-01

Cervical Cancer

Phase 1

Clinical Trials (1)

NCT05570422A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01

Phase 1

Help build intelligence for KORTUC

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a focused early-stage biotech with a novel radiosensitizer approach in high-unmet-need oncology indications
Japan-based headquarters may offer unique regulatory pathway advantages and access to Asian clinical trial networks
Pre-revenue stage allows for direct impact on program strategy and scientific direction during formative years

Watch Out For

Extreme early-stage risk: only 3 active clinical trials across Phase 1/2 with zero Phase 3 programs and no clear path to near-term value creation
No active hiring (zero open positions at time of data collection) suggests potential funding constraints or delayed expansion plans despite Series B status
Complete lack of published research or public visibility makes it difficult to assess scientific credibility or team expertise independently

Generated by Claude from KORTUC's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Hydrogen Peroxide

Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT02757651KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response

Phase 1/2

Hydrogen Peroxide

Breast Cancer

Phase 2

Clinical Trials (1)

NCT03946202KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2022

Portfolio: 3 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Marketed

Pipeline